Ann: Chairman's Address to Annual General Meeting, page-2

"PSMA-PET imaging has been endorsed by the major clinical guidelines in both the United States and Europe, and there is a high level of expectation amongst key opinion leaders that it will become the new standard in prostate cancer diagnosis and staging. We are well-positioned for success in this large market opportunity with a product we believe is highly differentiated from competitors. The early response to our Illuccix launch in the United States reaffirms market acceptance of the benefit that Illuccix can deliver to patients and clinicians alike."

"The Company currently has 20 active clinical trials across eight indications that it is sponsoring or supporting, including those in our core focus areas of prostate cancer, kidney cancer and glioblastoma, or brain cancer. This is a strong demonstration of our commitment to progressing the Company’s pipeline. It also reflects the high level of interest shown by clinical partners who are collaborating with Telix."

"This capital raise was a de-risking event for the company and its importance is clear given current market uncertainty. Telix now has the balance sheet to both execute its programs for the TLX250 renal diagnostic product and TLX101 glioblastoma imaging product; and advance the prostate, renal and glioblastoma therapeutic products towards regulatory approval submissions. We believe these activities will create new value for the Company over the next three years."

"In line with our governance principles the Board continues to ensure that it has the right mix of skills, diversity and independence. Accordingly, I am pleased to welcome MS Tiffany Olson to her first AGM as Non-Executive Director of the Company. Tiffany has a proven track record in commercial leadership in the radiopharmaceutical industry and appropriately now brings U.S. representation to the Board. Tiffany will be addressing the AGM shortly."

"The Company acknowledges and is grateful for the support of the Australian Government through the R&D tax incentive scheme which enables Telix to reinvest back into its R&D programs. We also recognise the value both to Telix and the broader Australian life sciences and manufacturing industries gained through the modern manufacturing initiative that Telix is participating in with local partners, GMS and Monash. Investment into advanced manufacturing is an important issue for both major parties in the current Australian Federal election, with Australian innovation and industry set to benefit from this commitment. Telix has strong industry ties including with the Australian Nuclear Science and Technology Organisation, or ANSTO, and looks forward to building on these relationships as Telix continues to grow."